BridgeBio Oncology
BBOT
66 hedge funds and large institutions have $451M invested in BridgeBio Oncology in 2026 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 18 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
2.05% more ownership
Funds ownership: 71.76% → 73.81% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
1% less funds holding
Funds holding: 67 → 66 (-1)
12% less capital invested
Capital invested by funds: $514M → $451M (-$63.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$12.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.76M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$5.4M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.85M |
| 5 |
AC
Armistice Capital
New York
|
+$3.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$7.77M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$6.44M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.7M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.42M |
| 5 |
RA
Royce & Associates
New York
|
-$2.1M |
BBOT Hedge Fund Activity: Q2 2026 in Review
66 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q2 2026, worth a combined $451M — down 12% from $514M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of BBOT and 17 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 21 added.
The largest buyer was Vanguard Capital Management, adding an estimated $12.2M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $7.77M sold.
- 66 institutional investors held BridgeBio Oncology (BBOT) as of Q2 2026, down from 67 in Q1 2026.
- Funds reported $451M of BridgeBio Oncology stock for Q2 2026, down 12% quarter-over-quarter.
- 17 funds opened new BridgeBio Oncology positions in Q2 2026 and 18 closed out, a net change of -1 holder.
- The largest BridgeBio Oncology buyer in Q2 2026 was Vanguard Capital Management, an estimated $12.2M added.
- The largest BridgeBio Oncology seller in Q2 2026 was Paradigm Biocapital Advisors, an estimated $7.77M sold.
Based on aggregated 13F filings for Q2 2026.